Document Type : Research Articles
Authors
1
Consultant in Hematology, Department of Medicine, Hospital de Carabineros de Chile, Simón Bolívar 2200, Ñuñoa, Santiago, Chile.
2
Professor Hematology and Head CTC Unit, Faculty of Medicine, University Finis Terrae, Av Pedro de Valdivia, Providencia, Santiago, Chile.
3
Consultant Urologist, Department of Urology, Hospital de Carabineros de Chile, Simón Bolívar, Ñuñoa, Santiago, Chile.
4
Consultant Urologist, Department of Urology, Hospital DIPRECA, Vital Apoquindo 1200, Las Condes, Santiago, Chile.
5
Faculty of Medicine, University Diego Portales, Manuel Rodríguez Sur 415, Santiago, Chile.
6
Physican General Medicine, Department of Medicine, Hospital de Carabineros de Chile, Simón Bolívar, Ñuñoa, Santiago, Chile.
7
Consultant Internal Medicine, Department of Medicine, Hospital de Carabineros de Chile, Simón Bolívar 2200, Ñuñoa, Santiago, Chile.
8
Tutor, Faculty of Medicine, University Mayor, San Pio X 2245, Providencia, Santiago, Chile.
Abstract
Introduction: An elevated serum PSA is the only biomarker routinely used in screening for prostate cancer to indicate a prostate biopsy. However, it is not specific for prostate cancer and the neutrophil/lymphocyte ratio has been suggested as an alternative. We present a prospective study of men with an elevated PSA and compare the neutrophil/lymphocyte ratio, free percent PSA, PSA density and the presence of circulating prostate cells to detect clinically significant prostate cancer at first biopsy. Patients and Methods: Prospective study of consecutive men with a PSA 4-10 ng/ml referred for initial prostate biopsy, the results were compared with the neutrophil/lymphocyte ratio, free percent PSA and PSA density. Circulating prostate cells (CPCs) were detected using immunocytochemistry. The blood sample was taken immediately before the prostate biopsy. Results: 1,223 men participated, 38% (467) of whom had prostate cancer detected, of these 322 were clinically significant. The area under the curves were for neutrophil/lymphocyte ratio, free percent PSA, PSA density and CPC detection were 0.570, 0.785, 0,620 and 0.844 respectively. Sensitivity/specificity were 0.388/0.685, 0.419/0.897, 0.598/0.624 and 0.966/0.786 respectively. The neutrophil/lymphocyte ratio did not differentiate between benign and malignant disease. Conclusions: The neutrophil/lymphocyte ratio did not discriminate between benign and malignant prostatic disease in patients with a PSA between 4-10ng/ml.
Keywords
Main Subjects
)